retatrutide 1 month results 3-Month Results: Weight Loss Clinical Data (2026) Tirzepatide vs. Retatrutide: Key Differences

This is attributed to the growing prevalence of type-2 diabetes and the growing number of clinical trials and research for treatment propelled the market

UK product information contains warnings about thyroid C-cell tumours based on animal studies, though clinical relevance to humans remains uncertain and Hashimoto's disease itself is not a contraindication

Evidence, Safety, and the Regulatory Landscape GLP-1 microdosing is biologically plausible, but its safety and effectiveness have not been validated in randomized clinical trials

What should you check before using a Retatrutide pen

Beyond Weight Loss: Metabolic Improvements Participants also saw improvements in cardiometabolic health markers: Blood pressure: Systolic BP decreased by 7.4 mmHg Triglycerides: Fell by 30% HDL cholesterol: Increased by 8% (the "good" cholesterol) Liver fat: Reduced by 50% based on imaging studies HbA1c: Decreased by 0.4% even in participants without diabetes Visceral fat: Reduced by 42% (more than total weight loss percentage) Some of these improvements (particularly the visceral and liver fat reductions) are larger than the overall weight loss, which points to direct metabolic effects from the glucagon receptor activation

These statements have not been approved by the Food and Drug Administration